By Denny Jacob

 

Eli Lilly's Jaypirca was approved by the Food and Drug Administration to treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.

The Indianapolis-based pharmaceutical company said Friday that Jaypirca was approved under the FDA's accelerated approval pathway based on results from a trial.

 

Write to Denny Jacob at denny.jacob@wsj.com

 

(END) Dow Jones Newswires

December 01, 2023 17:51 ET (22:51 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024 Click aqui para mais gráficos Eli Lilly.
Eli Lilly (NYSE:LLY)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024 Click aqui para mais gráficos Eli Lilly.